ATE389648T1 - 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten - Google Patents
4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonistenInfo
- Publication number
- ATE389648T1 ATE389648T1 AT00904889T AT00904889T ATE389648T1 AT E389648 T1 ATE389648 T1 AT E389648T1 AT 00904889 T AT00904889 T AT 00904889T AT 00904889 T AT00904889 T AT 00904889T AT E389648 T1 ATE389648 T1 AT E389648T1
- Authority
- AT
- Austria
- Prior art keywords
- heterocyclylsulfonamido
- pyridylpyrimidines
- methoxyphenoxy
- methoxy
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99100784 | 1999-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE389648T1 true ATE389648T1 (de) | 2008-04-15 |
Family
ID=8237359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00904889T ATE389648T1 (de) | 1999-01-18 | 2000-01-10 | 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten |
Country Status (31)
Country | Link |
---|---|
US (1) | US6242601B1 (ja) |
EP (1) | EP1149091B1 (ja) |
JP (1) | JP3983477B2 (ja) |
KR (1) | KR100478797B1 (ja) |
CN (1) | CN1340049A (ja) |
AR (1) | AR029879A1 (ja) |
AT (1) | ATE389648T1 (ja) |
AU (1) | AU763112B2 (ja) |
BR (1) | BR0007595A (ja) |
CA (1) | CA2359363C (ja) |
CO (1) | CO5150187A1 (ja) |
CZ (1) | CZ20012546A3 (ja) |
DE (1) | DE60038365D1 (ja) |
ES (1) | ES2301476T3 (ja) |
GC (1) | GC0000248A (ja) |
HR (1) | HRP20010515A2 (ja) |
HU (1) | HUP0200021A3 (ja) |
IL (2) | IL144055A0 (ja) |
MA (1) | MA27124A1 (ja) |
MY (1) | MY121136A (ja) |
NO (1) | NO322800B1 (ja) |
NZ (1) | NZ512662A (ja) |
PE (1) | PE20001421A1 (ja) |
PL (1) | PL350093A1 (ja) |
RU (1) | RU2224757C2 (ja) |
TR (1) | TR200102071T2 (ja) |
TW (1) | TWI284642B (ja) |
UY (1) | UY25904A1 (ja) |
WO (1) | WO2000042035A1 (ja) |
YU (1) | YU50001A (ja) |
ZA (1) | ZA200105279B (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
IL144144A0 (en) * | 1999-01-13 | 2002-05-23 | Bayer Ag | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
MY140724A (en) | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
BRPI0116237B8 (pt) | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
MEP36208A (en) * | 2001-12-03 | 2011-02-10 | Bayer Corp | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
AU2003210969A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
PT1580188E (pt) * | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aril-ureias como inibidores de cinases |
CA2475703C (en) | 2002-02-11 | 2016-12-20 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068229A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
CA2507334C (en) * | 2002-12-02 | 2013-05-07 | Actelion Pharmaceuticals Ltd. | Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
US7269460B2 (en) * | 2003-02-28 | 2007-09-11 | Medtronic, Inc. | Method and apparatus for evaluating and optimizing ventricular synchronization |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US20070020704A1 (en) | 2003-05-20 | 2007-01-25 | Scott Wilhelm | Diaryl ureas with kinase inhibiting activity |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
RU2435585C2 (ru) * | 2006-04-13 | 2011-12-10 | Актелион Фармасьютиклз Лтд | Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких |
ATE537144T1 (de) | 2006-05-29 | 2011-12-15 | Nicox Sa | Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
US10287263B2 (en) * | 2014-11-21 | 2019-05-14 | Daikin Industries, Ltd. | Fluorinated unsaturated cyclic carbonate and process for producing same |
CN109260164A (zh) * | 2018-10-07 | 2019-01-25 | 威海贯标信息科技有限公司 | 一种阿伏生坦片剂组合物 |
CN112778215B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用 |
CN112898208B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用 |
TW202329952A (zh) | 2021-12-17 | 2023-08-01 | 瑞士商愛杜西亞製藥有限公司 | 克拉生坦(clazosentan)二鈉鹽之製備方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837708A (en) | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
WO1996016963A1 (de) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
CA2162630C (en) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
TW313568B (ja) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
EP0882719B1 (en) * | 1995-12-20 | 2001-05-16 | Yamanouchi Pharmaceutical Co. Ltd. | Arylethenesulfonamide derivatives and drug composition containing the same |
-
2000
- 2000-01-07 TW TW089100181A patent/TWI284642B/zh not_active IP Right Cessation
- 2000-01-10 YU YU50001A patent/YU50001A/sh unknown
- 2000-01-10 TR TR2001/02071T patent/TR200102071T2/xx unknown
- 2000-01-10 DE DE60038365T patent/DE60038365D1/de not_active Expired - Lifetime
- 2000-01-10 CN CN00803754A patent/CN1340049A/zh active Pending
- 2000-01-10 PL PL00350093A patent/PL350093A1/xx not_active Application Discontinuation
- 2000-01-10 EP EP00904889A patent/EP1149091B1/en not_active Expired - Lifetime
- 2000-01-10 CZ CZ20012546A patent/CZ20012546A3/cs unknown
- 2000-01-10 KR KR10-2001-7008996A patent/KR100478797B1/ko not_active IP Right Cessation
- 2000-01-10 BR BR0007595-7A patent/BR0007595A/pt not_active Application Discontinuation
- 2000-01-10 RU RU2001122114/04A patent/RU2224757C2/ru not_active IP Right Cessation
- 2000-01-10 AT AT00904889T patent/ATE389648T1/de not_active IP Right Cessation
- 2000-01-10 WO PCT/EP2000/000103 patent/WO2000042035A1/en active IP Right Grant
- 2000-01-10 HU HU0200021A patent/HUP0200021A3/hu unknown
- 2000-01-10 NZ NZ512662A patent/NZ512662A/en unknown
- 2000-01-10 AU AU26630/00A patent/AU763112B2/en not_active Ceased
- 2000-01-10 IL IL14405500A patent/IL144055A0/xx not_active IP Right Cessation
- 2000-01-10 ES ES00904889T patent/ES2301476T3/es not_active Expired - Lifetime
- 2000-01-10 CA CA002359363A patent/CA2359363C/en not_active Expired - Fee Related
- 2000-01-10 JP JP2000593603A patent/JP3983477B2/ja not_active Expired - Lifetime
- 2000-01-13 PE PE2000000025A patent/PE20001421A1/es not_active Application Discontinuation
- 2000-01-13 US US09/482,810 patent/US6242601B1/en not_active Expired - Fee Related
- 2000-01-14 MY MYPI20000124A patent/MY121136A/en unknown
- 2000-01-14 UY UY25904A patent/UY25904A1/es unknown
- 2000-01-14 CO CO00001821A patent/CO5150187A1/es unknown
- 2000-01-14 AR ARP000100159A patent/AR029879A1/es unknown
- 2000-01-17 GC GCP2000481 patent/GC0000248A/en active
-
2001
- 2001-06-26 ZA ZA200105279A patent/ZA200105279B/en unknown
- 2001-06-28 IL IL144055A patent/IL144055A/en unknown
- 2001-07-10 HR HR20010515A patent/HRP20010515A2/hr not_active Application Discontinuation
- 2001-07-12 NO NO20013454A patent/NO322800B1/no unknown
- 2001-07-17 MA MA26270A patent/MA27124A1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE389648T1 (de) | 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten | |
ATE328871T1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
ATE299865T1 (de) | Piperazinderivate verwendbar als ccr5 antagonisten | |
ATE299866T1 (de) | Piperidinderivate verwendbar als ccr5 antagonisten | |
DE60022386D1 (de) | Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten | |
ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
ATE263151T1 (de) | Indolderivate verwendbar als endothelinrezeptorantagonisten | |
ATE400558T1 (de) | Metabotropische glutamatrezeptor-antagonisten | |
ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
DE60008262D1 (de) | Piperazinderivate als 5-ht1b antagonisten | |
ATE296825T1 (de) | 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten | |
DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
ATE400554T1 (de) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten | |
NO20015779L (no) | Bradykinin-reseptorantagonister | |
NO20016053D0 (no) | IL-8 reseptor-antagonister | |
DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
NO20020644D0 (no) | Nye integrinreseptor-antagonister | |
DE50100358D1 (de) | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten | |
ATE286018T1 (de) | Biphenylderivate als neurokinin-1 antagonisten | |
NO20016052L (no) | IL-8-reseptor-antagonister | |
NO20014224D0 (no) | 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister | |
ATE305001T1 (de) | Propansäure-derivate als integrin-rezeptor- antagonisten | |
DK1180028T3 (da) | IL-8-receptorantagonister | |
ATE264301T1 (de) | Muscarin-antagonisten | |
NO20021113D0 (no) | Vitronectin-reseptor-antagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |